Winterlight Labs secures additional seed funding ($1,000,000) from American investors to commercialize speech-based detection of cognitive impairments

TORONTO, August 25, 2018

Winterlight Labs, a Toronto-based company commercializing a speech-based platform for accurately detecting cognitive conditions such as dementia and Alzheimer’s Disease, recently closed $1,000,000 in additional seed funding from Grey Sky Venture Partners (GSVP), based on Bellevue Washington.

In total Winterlight Labs has raised $1.5 million in seed funding from two venture capital firms, GSVP & Novatio, to help develop its software, collect data and refine it's machine learning algorithms.

About Winterlight Labs

Winterlight Labs is commercializing a proprietary language-based diagnostic system that analyzes natural speech to detect and monitor dementia, Alzheimer’s, aphasia, and various other cognitive conditions. Winterlight's scalable platform uses short recorded speech samples to analyze hundreds of linguistic cues, and can detect dementia and other conditions with a high level of accuracy. This is a major improvement over current pencil-and-paper tests which are time-consuming, costly, and difficult to administer. The platform has applications in drug trials, long-term and primary care, and speech-language pathology.

Since its founding, Winterlight Labs has seen strong interest from pharmaceutical companies and other potential partners who view the technology as a major improvement over current methods of detection or screening. The company has gained support from the pan-Canadian AGE-WELL Network of Centres of Excellence (NCE), the Ontario Brain Institute, Ontario Centres of Excellence, and the University of Toronto Banting and Best Centre for Innovation and Entrepreneurship. For more information, visit

Media Inquiries:
Winterlight Labs
Liam Kaufman, CEO
liam [at]